Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab (SHR-1210) and GVD Chemotherapy with or without Decitabine for rrPMBCL
NCT03346642Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2017
- Primary completion
- Mar 2019
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT03346642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03346642.